New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Abcellera, Affimed, Alligator, Allogene, Ankyra, Calidi, Candel, CDR-Live, Hotspot, Scopus.
Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways.
Researchers from Genequantum Healthcare (Suzhou) Co. Ltd. have presented the first preclinical data on GQ-1007, an antibody immune agonist conjugate (AIAC) targeting HER2, for the treatment of cancer. GQ-1007 is an anti-HER2 antibody conjugated via Genequantum’s highly stable linker and enzymatic conjugation technology to a Toll-like receptor 7/8 (TLR7/8) agonist.
At the Society for Immunotherapy of Cancer’s annual meeting, researchers from Tallac Therapeutics Inc. reported the discovery of TAC-003, a novel Toll-like receptor 9 (TLR9) agonist and Nectin-4-specific antibody conjugate, being developed as cancer immunotherapy candidate.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Akeso, Antengene, Asher Biotherapeutics, Bioinvent International, Carisma Therapeutics, Catalym, Coeptis Therapeutics, Context Therapeutics, Corbus Pharmaceuticals, Gracell Biotechnologies, Lyell Immunopharma.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting in Boston, by:
GI Cell, Maia Biotechnology.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting in Boston, by: Ankyra, Antengene, Artiva, Asher, Bluesphere, Catamaran, Cellectis, Century, Cytoimmune, Domain, Iconovir, Immunitas, Imugene, Imvax, Triumvira Immunologics, Tscan, Umoja.
RSS
